HEMGENIX - AN OVERVIEW

Variety of eligible patients: CDEC discussed the uncertainty in the number of patients with moderately severe to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some individuals who're labeled as having moderate or moderate sickness can have a critical bleeding phenotype, which w